Apria APR 深 沪
等待开盘 12-16 09:30:00 美东时间
37.50
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 37.50
- 总市值 13.40亿
- 52周最高 40.00
- 市盈率 静 20.53
- 换手率 0.00%
- 52周最低 25.01
- 委 比 0.00%
- 总股本 3574.13万
- 历史最高 40.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 20.07
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Delinquency rate rises, net charge-offs dip: September Credit Pulse
U.S. credit card delinquencies continued to rise last month even as net charge-off rates fell, signaling more borrowers were falling behind but a smaller share of balances were being written off. Both...
10-28 02:19
Sensor Tower：2025年全球手游内购收入有望增至854亿美元 预计韩国市场收入达53亿美元
2025年全球手游内购收入有望再增6%至854亿美元，Steam平台游戏购买收入预计增长12%达到119亿美元。
10-27 11:14
Aprea To Feature Preliminary Results From ACESOT-1051 Trial Through September 17 In Poster Presentation At AACR-NCI-EORTC
3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in patients with tumors
10-24 20:35
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
<p>Aprea Therapeutics reported early results from its Phase 1 ACESOT-1051 trial, showing that 75% of heavily pretreated gastrointestinal and gynecologic cancer patients achieved stable disease at the 100 mg dose of APR-1051, its WEE1 kinase inhibitor. Disease stabilization was observed in tumors with mutations relevant to WEE1 inhibition, including FBXW7, CCNE1, KRAS G12V, and TP53. Dose escalation continues, with patients now enrolling in the 15...
10-24 12:30
Flexible Payments Come To All Wayfair Stores Thanks To Affirm
Affirm expands partnership with Wayfair, integrating pay-over-time solution at checkout. Move simplifies payments for shoppers.
10-21 23:48
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development...
10-21 20:05
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
Aprea Therapeutics identified the recommended Phase 2 dose of 1,100 mg once daily for ATRN-119, an oral ATR inhibitor, in the monotherapy arm of its ABOYA-119 Phase 1/2a study for patients with advanced solid tumors. The company is pausing further enrollment in monotherapy arms to focus on strategic high-value combinations, such as DNA-damaging agents and immune checkpoint inhibitors, based on preclinical data suggesting synergistic anti-tumor ef...
10-15 12:00
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
Aprea Therapeutics announced that two abstracts for its clinical programs, APR-1051 and ATRN-119, have been accepted for poster presentations at the EORTC-NCI-AACR conference in Boston. Both presentations will occur on October 24th during Poster Session B in Exhibit Hall D. APR-1051 is a WEE1 inhibitor targeting cancer-associated gene alterations, while ATRN-119 is an ATR inhibitor for advanced solid tumors with DNA damage. The posters will be av...
10-14 12:00
Block’s Cash App post-purchase BNPL is gaining steam, could lift EPS growth: UBS
Block’s (NYSE:XYZ) newest lending feature inside Cash App, the ability to convert recent Cash App Card purchases into installment plans, has scaled quickly since launching in February and could become...
10-13 03:17
